Market capitalization | $8.89b |
Enterprise Value | $8.67b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 45.56 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-144.53m |
Free Cash Flow (TTM) Free Cash Flow | $-96.67m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:
3 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.25 -1.25 |
-
|
|
EBITDA | -143 -143 |
118%
118%
|
EBIT (Operating Income) EBIT | -145 -145 |
113%
113%
|
Net Profit | -162 -162 |
73%
73%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
Head office | United Kingdom |
CEO | Robert Zanganeh |
Employees | 105 |
Founded | 2003 |
Website | www.smmttx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.